Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
McKinsey
AstraZeneca
Merck
Citi
Johnson and Johnson
Farmers Insurance
Chubb
Harvard Business School

Generated: December 10, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR REMIFENTANIL HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Remifentanil Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT00158873 Pharmaco-Economic Study Of Ultiva In Intensive Care Unit(ICU)Subjects Completed GlaxoSmithKline Phase 4 The study will evaluate the pharmaco-economic consequences of the use of a remifentanil based regimen compared with a conventional sedative based regimen in terms of duration of mechanical ventilation, length of stay in ICU, difference in extubation time and use of concomitant sedative agents.
NCT00162591 Bispectral Index as an Analgesia Monitoring in Severely Ill Patient: Effect of Remifentanyl Unknown status Assistance Publique - Hôpitaux de Paris N/A The aim of this protocol is to study the prophylactic effect of remifentanil on bispectral index variation during a nociceptive stimuli.
NCT00202722 Remifentanil as Intravenous Patient-controlled Analgesia (IVPCA) During Labour Completed Sorlandet Hospital HF Phase 4 Remifentanil is a ultra short-acting synthetic opioid. It is rapidly metabolized by non-specific blood and tissue esterases. We wanted to investigate the efficacy and safety of remifentanil used as analgesia during labour. Intravenous patient controlled analgesia (ivpca) were used to administer remifentanil. Doses used were 0,15-1,05 mikrogr/kg, with a lock-out time of 2 minutes. 41 women were included in the study. Blood-pressure, heartrate, SaO2, respiration rate and sedation were recorded every 15.minute. Fetal heart rate was recorded for the whole periode of treatment (CTG, STAN). Vaginal contraction pain were assessed by the parturients every 15.minute using a Visual Analogue Scale (VAS). Midwives also recorded their impression of the parturients pain. The parturients level of sedation were recorded by anesthesiologist and midwife every 15.minute. Apgar scores were registered at 1, 5 and 10 min after delivery. Umbilical cord blood analysis regarding blood gases and concentration of remifentanil were performed. After delivery, both mother and midwife evaluated efficacy and safety; Global satisfaction score, if the remifentanil doses were sufficient, nausea, vomiting, level of sedation and dizziness.
NCT00209872 Optimal Multimodal Analgesia in Abdominal Hysterectomy Unknown status Hvidovre University Hospital Phase 4 The purpose of this study is to test the current standard of care (SOC) treatment for abdominal hysterectomy with a group receiving SOC minus epidural analgesia plus additional perioperative analgesics in terms of postoperative abilities, postoperative nausea and vomiting (PONV), pain and discharge time from the PACU (post-anaesthesia care unit).
NCT00209885 Optimal Multimodal Analgesia in Laparoscopic Cholecystectomy Unknown status Hvidovre University Hospital Phase 4 To test the current standard of care (SOC) treatment for laparoscopic cholecystectomy with a group receiving SOC + additional perioperative analgesics in terms of postoperative abilities, PONV, pain and discharge time from the PACU
NCT00213239 A Dose Finding Study of Remifentanil and Propofol for Lumbar Punctures in Children Completed The Hospital for Sick Children Phase 1/Phase 2 This study will examine whether the combination of two anaesthetic medications, propofol and remifentanil, is suitable for short duration surgical procedures, providing a shorter recovery time and fewer side effects than either drug used alone.
NCT00241332 Postoperative Pain After Orthopedic Surgery: Does it Help to Give Fentanyl Before Start of Remifentanil Based Anesthesia? Completed University of Oslo Phase 3 The aim of this trial is to examine the possibility that fentanyl 1,5 µgr/kg given intravenously (i.v.) before the start of remifentanil infusion for anesthesia gives less development of tolerance/hyperalgesia postoperative than fentanyl given at the end of surgery (the traditional method).
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Remifentanil Hydrochloride

Condition Name

Condition Name for Remifentanil Hydrochloride
Intervention Trials
Anesthesia 64
Pain 35
Postoperative Pain 20
Pain, Postoperative 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Remifentanil Hydrochloride
Intervention Trials
Pain, Postoperative 37
Hyperalgesia 18
Postoperative Nausea and Vomiting 12
Vomiting 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Remifentanil Hydrochloride

Trials by Country

Trials by Country for Remifentanil Hydrochloride
Location Trials
Korea, Republic of 87
United States 55
France 41
China 28
Canada 28
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Remifentanil Hydrochloride
Location Trials
Ohio 10
Illinois 7
New York 6
Texas 6
North Carolina 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Remifentanil Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Remifentanil Hydrochloride
Clinical Trial Phase Trials
Phase 4 211
Phase 3 35
Phase 2/Phase 3 4
[disabled in preview] 41
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Remifentanil Hydrochloride
Clinical Trial Phase Trials
Completed 255
Recruiting 91
Unknown status 44
[disabled in preview] 83
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Remifentanil Hydrochloride

Sponsor Name

Sponsor Name for Remifentanil Hydrochloride
Sponsor Trials
Yonsei University 29
Ajou University School of Medicine 15
Hopital Foch 12
[disabled in preview] 33
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Remifentanil Hydrochloride
Sponsor Trials
Other 579
Industry 37
U.S. Fed 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Fuji
UBS
Chubb
QuintilesIMS
Daiichi Sankyo
Johnson and Johnson
Argus Health
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.